Bob Hopkins

In a report published Thursday, Bank of America Merrill Lynch analyst Bob Hopkins downgraded the rating on Baxter International Inc (NYSE: BAX) from Buy to Neutral, while lowering the price target from $78 to $40. Although the company is likely to be an interesting "margin story" following its...

In a report published Friday, Bank of America analyst Bob Hopkins reiterated a Buy rating on Intuitive Surgical, Inc. (NASDAQ: ISRG), and raised the price target from $550.00 to $600.00. In the report, Bank of America noted, “In this note we highlight our updated procedure volume growth model with...

Bank of America raised its price target on Intuitive Surgical, Inc. (NASDAQ: ISRG) Monday from $550 to $600 and maintained a Buy rating. Analysts led by Bob Hopkins commented that “ISRG is up over 30 percent this year due in large part to reaccelerating procedure volume growth (PVG)...

In a report published Tuesday, Bank of America analyst Bob Hopkins reiterated a Neutral rating on Edwards Lifesciences Corp. (NYSE: EW), and raised the price target from $120.00 to $140.00. In the report, Bank of America noted, “EW's annual analyst day was held yesterday morning in New York. All...

In a report published Friday, Bank of America analyst Bob Hopkins reiterated a Buy rating on Medtronic (NYSE: MDT), and raised the price target from $80.00 to $85.00. In the report, Bank of America noted, “Following the debt financing of the COV deal earlier this week we are adjusting our model and...

In a report published Friday, Bank of America analyst Bob Hopkins reiterated a Buy rating on Medtronic (NYSE: MDT), and raised the price target from $80.00 to $85.00. In the report, Bank of America noted, “Following the debt financing of the COV deal earlier this week we are adjusting our model and...

Bob Hopkins of Bank of America attended the AAGL 2014 Global Congress on Minimally Invasive Gynecology last week and were impressed with the feedback received by Intuitive Surgical, Inc. (NASDAQ: ISRG). Hopkins notes that feedback on Intuitive Surgical's new wristed, single-site needle...

In a report published Wednesday, Bank of America analyst Bob Hopkins reiterated a Neutral rating on Johnson & Johnson (NYSE: JNJ), but lowered the price target from $106.00 to $99.00. In the report, Bank of America noted, “JNJ reported a solid Q3, but also highlighted a number of likely EPS...

In a report published Tuesday, Bank of America analyst Bob Hopkins moved the rating on CareFusion Corporation (NYSE: CFN) from Buy to No Rating, and removed the $50.00 price target. In the report, Bank of America noted, “On Sunday night, BDX announced it had entered into a definitive agreement to...

In a report published Monday, Bank of America analyst Bob Hopkins reiterated a Buy rating and $80.00 price target on St. Jude Medical, Inc. (NYSE: STJ). In the report, Bank of America noted, “Given F/X moves since STJ's Q2 call and STJ's guidance that roughly 45-50% of every dollar of revenue...

In a report published Monday, Bank of America analyst Bob Hopkins reiterated a Buy rating on Baxter International Inc. (NYSE: BAX), but lowered the price target from $84.00 to $80.00. In the report, Bank of America noted, “Some reasons we see to own BAX are the core markets Baxter's bioscience...

In a note issued Thursday morning, Bank of America analyst Bob Hopkins reinstated coverage of Medtronic, Inc. (NYSE: MDT) with a Buy rating and a $75 price objective. Hopkins explained the reason driving the Buy rating is Medtronic's proposed acquisition of Covidien plc (NYSE: COV), which he...

In a report published Friday, Bank of America analyst Bob Hopkins reiterated a Neutral rating and $106.00 price target on Johnson & Johnson (NYSE: JNJ). In the report, Bank of America noted, “Yesterday, the Wall Street Journal reported that JNJ will seek a buyer for its Cordis division, which...

In a note dated July 29, Bank of America analyst Bob Hopkins downgraded shares of C.R. Bard (NYSE: BCR) from Neutral to Underperform and maintained a $150 price objective. Hopkins noted that he made no change to and has no more or less conviction in his revenue and earnings assumptions or his price...

In a report published Thursday, Bank of America analyst Bob Hopkins reiterated a Neutral rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $39.00 to $46.00. In the report, Bank of America noted, “We expect ABT to continue to grow earnings in the double-digit range on an...